News 2016
OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer
Background: Globo H is a glycolipid that is highly expressed in breast cancer (BC). Active immunotherapy with OPT-822, a Globo H-KLH conjugate, and the adjuvant OPT-821 in two phase 1 …
OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Oral Presentation Highlights the Results of a Phase II/III Trial of the Investigational Immunotherapy OBI-822/OBI-821 in Patients with Metastatic Breast Cancer TAIPEI, TAIWAN, May 19, 2016 – OBI Pharma, Inc., …
Company Position Statement Regarding Recent Investigation of Senior Executives
OBI Pharma strongly denies allegations of insider trading. Since March 2016, the Shi-Lin District Prosecutor’s Office has been investigating whether senior OBI executives sold shares with foreknowledge of the results …
OBI Pharma Announces Decision By ASCO to Accept its Abstract for Oral Presentation at ASCO’S 2016 Annual Meeting
OBI Pharma, Inc. today announced that the American Society of Clinical Oncology (ASCO) has formally accepted its abstract regarding the results of its Phase 2/3 study of OBI-822/821 (formerly OPT‐822/OPT‐821), …
OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer
Plans to Advance to Global Phase 3 Clinical Program TAIPEI, TAIWAN, February 21, 2016 — OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced the topline results of …